Arrhythmias & electrophysiologyCohort study
Class Ic antiarrhythmic therapy after percutaneous coronary intervention (PCI) in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort
- retrospective cohort study
Authors' conclusion
In patients with CCS who developed NOAF, the use of class Ic AADs was associated with significantly lower risks of MACEs, all-cause mortality, and cerebrovascular events and without an increased risk of ventricular arrhythmia. These findings suggest that class Ic agents may be a safe and effective option for rhythm control in carefully selected patients with CCS.
Study context
- Population
- Adults with new-onset atrial fibrillation (NOAF) after PCI, Taiwan's National Health Insurance Research Databasemean age 74.70, 69.33% male, CHA2DS2-VASc score 3.98
- Participants
- 3,750 adults
- Exposure
- class Ic AADs compared with nonuse in patients with new-onset atrial fibrillation (NOAF) after PCI
Main finding
Major adverse cardiovascular events (MACEs)
asHR
0.64
95% CI 0.59–0.68
P < 0.01
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | asHR (95% CI) | P value |
|---|---|---|
| All-cause mortality | 0.61 (0.57–0.66) | P < 0.01 |
| Cerebrovascular events | 0.81 (0.66–0.99) | P = 0.04 |
Safety
| Outcome | asHR (95% CI) | P value |
|---|---|---|
| Ventricular arrhythmia · No increased risk | 0.89 (0.69–1.15) | P = 0.37 |
Original publication
Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort. Heart Rhythm. Published 5 March 2026. doi:10.1016/j.hrthm.2026.02.042
Summarised from the published abstract; every number is checked against it